Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan, Gemcitabine, and Nab-Paclitaxel in Unresectable Pancreatic Cancer
NCT04158635Phase 1Suspended
- Sponsor
- City of Hope
- Start
- Sep 2021
- Primary completion
- Mar 2027
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of bosentan in pancreatic cancer (PC) (3 arms), sponsored by City of Hope. Primary endpoints: Incidence of adverse events, Dose limiting toxicities up to 21 days and 1 more. Started Sep 2021; status: suspended.
02
Drugs
bosentan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04158635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158635.